GO:1904855 proteasome regulatory particle binding

The proteasome is the major proteolytic machine in eukaryotic cells, responsible for degrading the majority of intracellular proteins in a ubiquitin-dependent manner. The proteasome holoenzyme consists of a barrel-shaped 20S core particle (CP) that houses the catalytic sites and one or two 19S regulatory particles (RPs) that cap the core and control substrate access. The 19S regulatory particle, also known as PA700, is a ~900 kDa complex composed of at least 19 subunits, including six AAA+ ATPases (Rpt1-6) and multiple non-ATPase subunits (Rpn1-3, Rpn5-13, Rpn15). The term GO:1904855, proteasome regulatory particle binding, refers to the molecular function of selectively and non-covalently interacting with the proteasome regulatory particle. This binding event is central to proteasome biology because it underlies the recruitment of ubiquitinated substrates, the assembly and quality control of the regulatory particle, and the coordination of degradation with cellular signaling. Researchers study proteasome regulatory particle binding to understand how cells maintain protein homeostasis and how this process goes awry in disease. For example, substrate receptors such as Rpn10 and Rpn13 bind the regulatory particle and recognize ubiquitin chains on target proteins, thereby dictating which proteins are degraded. Assembly chaperones, including Hsm3, Nas2, Nas6, and Rpn14, transiently bind the regulatory particle to ensure correct subunit incorporation. Moreover, deubiquitinating enzymes like Rpn11 and Usp14 associate with the regulatory particle and regulate substrate fate. The functional analysis of the regulatory particle has been greatly advanced by genetic and biochemical studies in yeast and mammalian cells. Given the broad impact of proteasome function on cell cycle, apoptosis, immune response, and stress responses, understanding the molecular details of regulatory particle binding is essential for both basic biology and therapeutic development. This article provides a comprehensive overview of GO:1904855, covering its definition, biological significance, key genes, regulatory mechanisms, disease associations, and state-of-the-art research methods including CRISPR-based models.

GO:1904855, proteasome regulatory particle binding, is defined as the binding to a proteasome regulatory particle. In other words, it is the molecular function of a protein or other molecule physically interacting with the 19S regulatory particle (also called PA700 or the modulator complex) of the 26S proteasome. This binding can be transient or stable and is typically mediated by specific structural domains or motifs. The term encompasses interactions that occur during regulatory particle assembly, substrate recognition, and allosteric regulation of proteasome activity.

Proteasome regulatory particle binding is critically important because it governs the specificity and efficiency of protein degradation, a process that controls virtually every aspect of cellular physiology. The regulatory particle recognizes ubiquitinated substrates, removes ubiquitin chains, unfolds the substrate, and translocates it into the 20S core for proteolysis. Proteins that bind the regulatory particle, such as substrate receptors and assembly chaperones, determine which proteins are degraded and ensure the proteasome is properly assembled. Defects in these interactions lead to accumulation of damaged or misfolded proteins, which is a hallmark of many diseases including cancer and neurodegeneration. Therefore, studying GO:1904855 provides mechanistic insights into protein homeostasis and identifies potential therapeutic targets.

The following genes encode proteins that bind the proteasome regulatory particle or are subunits of the regulatory particle itself, and they are frequently studied in the context of GO:1904855.

The binding of proteins to the proteasome regulatory particle is regulated at multiple levels. Transcriptional regulation controls the abundance of regulatory particle subunits and associated factors, ensuring stoichiometric assembly. Post-translational modifications, including phosphorylation by kinases such as CK2 and PKA, modulate the interactions between regulatory particle subunits and their binding partners. Additionally, the availability of assembly chaperones is tightly regulated to prevent premature or aberrant assembly. Cellular stress conditions, such as oxidative stress or heat shock, can alter the binding of proteins like TXNL1 to the proteasome, thereby adapting degradation capacity to stress. Furthermore, the ubiquitin-proteasome system is integrated with autophagy and other degradation pathways, and cross-talk between these systems influences regulatory particle binding.

Dysregulation of proteasome regulatory particle binding is implicated in multiple cancers. Overexpression of PSMD4 (Rpn10) and ADRM1 (Rpn13) has been observed in various tumors and is associated with poor prognosis. Proteasome inhibitors like bortezomib target the 20S core but their efficacy can be influenced by regulatory particle composition and substrate binding. Mutations in genes encoding regulatory particle subunits or binding proteins can lead to altered degradation of oncoproteins and tumor suppressors, contributing to tumorigenesis.

Impaired proteasome function is a hallmark of neurodegenerative diseases such as Alzheimer's and Parkinson's, where accumulation of ubiquitinated protein aggregates is observed. Defects in regulatory particle binding, particularly in substrate receptors or shuttling factors, can exacerbate protein aggregation and neuronal toxicity. For example, mutations in UBQLN2, a shuttling factor that binds the proteasome, cause amyotrophic lateral sclerosis (ALS). Enhancing proteasome activity by modulating regulatory particle binding is a potential therapeutic strategy.

Proteasome dysfunction contributes to cardiac hypertrophy and heart failure, where altered degradation of signaling proteins affects cardiomyocyte growth. In metabolic disorders, impaired proteasome activity in pancreatic beta cells can lead to insulin resistance and diabetes. Regulatory particle binding proteins are therefore potential targets for therapeutic intervention in these conditions.

Affinity purification coupled with mass spectrometry (AP-MS) is widely used to identify proteins that bind the proteasome regulatory particle. By tagging a regulatory particle subunit or a candidate binding protein, researchers can isolate native complexes and determine their composition. Quantitative proteomics, such as SILAC or TMT, allows comparison of binding partners under different conditions. These methods have revealed dynamic interactions between the regulatory particle and shuttling factors, deubiquitinases, and assembly chaperones.

Cryo-electron microscopy (cryo-EM) and X-ray crystallography have provided high-resolution structures of the 26S proteasome and its regulatory particle, revealing the molecular details of subunit interactions and substrate binding. Recent structures of the TXNL1-bound proteasome have illuminated how accessory proteins dock onto the regulatory particle. These techniques are essential for understanding the conformational changes that occur during substrate recognition and translocation.

In vitro degradation assays using purified proteasomes and ubiquitinated substrates measure the efficiency of substrate binding and processing. ATPase activity assays monitor the catalytic cycle of the Rpt subunits. Additionally, cell-based assays such as cycloheximide chase or fluorescent reporters (e.g., Ub-GFP) assess proteasome activity in vivo. These functional assays are critical for linking structural and biochemical data to cellular outcomes.

Genome-wide CRISPR knockout screens have been used to identify genes that regulate proteasome function and regulatory particle binding. By selecting for cells that survive proteasome inhibition or accumulate specific substrates, researchers can uncover novel components of the regulatory particle assembly and substrate recruitment pathways. These screens are powerful for discovering new therapeutic targets.

Researchers studying proteasome regulatory particle binding-related genes often need to determine whether a candidate gene is causally involved in proteasome function, substrate recognition, or disease progression. CRISPR-based models provide a robust way to test these hypotheses by precisely manipulating the genome.

GO:1904855, proteasome regulatory particle binding, is a fundamental molecular function that governs the interaction of proteins with the 19S regulatory particle of the proteasome. This binding event is essential for substrate recognition, proteasome assembly, and the regulation of protein degradation, impacting diverse cellular processes and human diseases. Understanding the mechanisms and key players involved in regulatory particle binding provides a foundation for developing targeted therapies and advanced research models. With the help of CRISPR-based tools and EDITGENE's services, researchers can continue to unravel the complexities of this critical interaction.